The robust efficacy and clean safety profile de-risk bempikibart's path to registration in alopecia areata. Monitor for FDA feedback and initiation of Phase 3 trial in 1H27, which could drive significant upside for this $190M market cap biotech. The data also supports expansion into other I&I indications.
Price Chart
Executive Summary
Q32 Bio announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a trial for bempikibart in severe/very severe alopecia areata. The mITT population (n=25) showed a 35.3% mean SALT reduction and 40.0% SALT-20 response, with no Grade 3 or higher adverse events and negligible anti-drug antibodies. The company plans to advance to a registration-directed program and engage the FDA in 1H27, supporting a differentiated biologic profile in a >$5B US market opportunity.
Key Facts
- Part B mITT (n=25): 35.3% mean SALT reduction at Week 36; SALT-20 response 40.0% (10/25)
- ITT (n=33): SALT-20 response 30.3% (10/33)
- No Grade 3 or higher AEs; injection site reactions in 4% of administrations, all mild
- Negligible anti-drug antibodies with no impact on pharmacokinetics
- Plans to initiate registration-directed program in 1H27 after FDA engagement
- US alopecia areata market estimated >$5B by 2037
Financial Impact
No financial data in filing; positive clinical data supports potential for partnership or funding for registrational trials
Risk Factors
- Small sample size (n=25 mITT) limits statistical power; results may not replicate in larger trials
- Company will need additional capital to fund registrational trials; dilution risk
- Competition from JAK inhibitors with established market presence and black box warnings may limit uptake
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-301520 |
| Document: d143274d8k.htm | 0001193125-26-301520 |
| Document: 0001193125-26-301520-index-headers.html | 0001193125-26-301520 |
| Document: 0001193125-26-301520-index.html | 0001193125-26-301520 |
| Document: 0001193125-26-301520.txt | 0001193125-26-301520 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $10.91 $10.47 | ▼ −4.03% | ▼ −4.14% | $8.23 (−24.56%) |
Aug 27, 2026 5w ago | Insider Cluster | $16.15 $12.80 | ▼ −20.74% | ▼ −21.01% | $8.23 (−49.04%) |
Aug 5, 2026 8w ago | 8-K | $16.49 $15.37 | ▼ −6.79% | ▼ −7.14% | $8.23 (−50.09%) |
Jul 15, 2026 11w ago | Press Release | $15.70 $15.08 | ▲ +3.95% | ▲ +2.97% | $8.23 (+47.58%) |
Jul 14, 2026 11w ago | EFFECT | $18.46 $15.04 | ▼ −18.53% | ▼ −17.23% | $8.23 (−55.42%) |
Jul 13, 2026 11w ago | 8-K | $21.38 $15.05 | ▼ −29.61% | ▼ −28.82% | $8.23 (−61.51%) |
Jul 13, 2026 11w ago | 8-K | $21.38 $15.05 | ▼ −29.61% | ▼ −28.82% | $8.23 (−61.51%) |
Jun 25, 2026 14w ago | S-3 | $13.17 $13.09 | ▼ −0.61% | ▼ −2.77% | $8.23 (−37.51%) |
Jun 2, 2026 17w ago | Insider Cluster | $12.64 $11.89 | ▼ −5.93% | ▼ −2.97% | $8.23 (−34.89%) |
May 5, 2026 21w ago | 8-K | $5.14 $5.81 | ▲ +13.04% | ▲ +11.05% | $8.23 (+60.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access